A Study of the Efficacy and Safety of QLT091001 in Subjects with Inherited Retinal Disease (IRD) Caused by Mutation in Retinal Pigment Epithelium Protein 65 (RPE65) or Lecithin : Retinol Acyltransferase (LRAT)

A Study of the Efficacy and Safety of QLT091001 in Subjects with Inherited Retinal Disease (IRD) Caused by Mutation in Retinal Pigment Epithelium Protein 65 (RPE65) or Lecithin : Retinol Acyltransferase (LRAT).

Type: Interventional

Status of the trial: Completed

Orphan Drug Recognition: Yes

Inclusion

Opening Date: 2016-09-06
Closing Date: 2019-09-06

Criteria

More information

Children: Yes

Adults: Yes

Funder Type: industry

HCP: Principal investigators

Centre for Ophthalmology, University Eye Hospital, Tübingen, Germany

HCP: Other investigators

Within ERN-EYE members

Principal investigators

Other investigators

Workgroups

Retinal Rare Eye Diseases (WG1)

A Study of the Efficacy and Safety of QLT091001 in Subjects with Inherited Retinal Disease (IRD) Caused by Mutation in Retinal Pigment Epithelium Protein 65 (RPE65) or Lecithin : Retinol Acyltransferase (LRAT)

Within ERN-EYE members

Subscribe

This ERN is supported by: